Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4

Conditions

Melanoma 4Skin Neoplasms 1Neoplasm Metastasis 1Diabetes Mellitus, Insulin-Dependent, 12 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 136Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 68fludarabine phosphate 62Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Specimen Handling 36Cisplatin 36CTLA-4 Antigen 36Magnetic Resonance Spectroscopy 35Carboplatin 35cobimetinib 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Melanoma × tilsotolimod × Dermatologic × Clear all
NCT03445533 2022-11-08

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Idera Pharmaceuticals, Inc.

Phase 3 Terminated
481 enrolled 22 charts
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT02644967 2022-08-03

ILLUMINATE-204

Idera Pharmaceuticals, Inc.

Phase 2 Completed
53 enrolled 21 charts
Dermatologic

Melanoma

NCT04126876 2021-04-15

INTRIM

Amsterdam UMC, location VUmc

Phase 2 Recruiting
214 enrolled
Dermatologic

Melanoma

NCT03052205 2020-02-11

ILLUMINATE-101

Idera Pharmaceuticals, Inc.

Phase 1 Completed
54 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡